However, this original CD4-Ig faced three main limitations: it had prohibitively short in vivo half-life, its potency was lower than most HIV-1 broadly neutralizing antibodies26, 29, and it enhanced infection at low concentrations in cell-culture assays, by promoting interaction of the HIV-1 Env to the coreceptor CCR5. This evidence concerns the gene CD4 and infection.